Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab Added to Total Therapy in Newly Diagnosed High-Risk Multiple Myeloma
NCT03004287Phase 2Active, not recruiting
- Sponsor
- University of Arkansas
- Start
- Jul 2017
- Primary completion
- Oct 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by University of Arkansas. Started Jul 2017; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03004287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03004287.